Pulmonary Vein Isolation in Athletes

Atrial Fibrillation Clinical Trial

Official title:

Pulmonary Vein Isolation in Athletes: Effects on Peak Performance and Pulmonary Vein Function

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03226847
• Other study ID #: 17-584
• Status: Completed
• Phase: N/A
• Start date: July 17, 2017
• Est. completion date: March 16, 2021

Study information

• Verified date: December 2021
• Source: The Cleveland Clinic
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pulmonary vein isolation (PVI) has become a common and effective treatment for paroxysmal and persistent atrial fibrillation (AF), particularly in patients with drug-refractory disease. Intense endurance exercise is a known risk factor for atrial fibrillation. In general, these athletes poorly tolerate most common antiarrhythmic drugs used for atrial fibrillation control and often PVI is recommended for durable management. While the efficacy of PVI in athletes is similar to the general AF population, some athletes with lone atrial fibrillation report a reduction in subjective exertional capacity following PVI, despite maintenance of sinus rhythm and absence of pulmonary vein stenosis on imaging. The investigators hypothesize that PVI may alter pulmonary vein function and affect peak exercise performance. The investigators propose a small, prospective study of endurance athletes undergoing antral PVI for treatment of lone atrial fibrillation. Peak metabolic performance and pulmonary vein function will be assessed pre- and post-PVI by metabolic stress testing and cardiac MRI, respectively.

Description:

Endurance athletes with paroxysmal or persistent atrial fibrillation undergoing primary pulmonary vein isolation will be prospectively enrolled prior to PVI. Patients will undergo metabolic exercise stress testing as well as resting CMR 1-4 weeks prior to PVI. Metabolic stress testing and CMR will be repeated at 6 month follow-up. Quality of life questionnaires will also be collected at pre- and post-PVI visits. Metabolic treadmill stress testing will follow standard protocol and measure hemodynamics with escalating metabolic output and characterize peak exercise capacity (METs) and oxygen consumption (VO2 max). CMR evaluation will include standard anatomic imaging of pulmonary vein and left atrial anatomy at rest. Additional cine CMR sequences willbe included for focused evaluation of dynamic pulmonary vein cross-sectional area. 3D navigator whole heart imaging and MRA (single gadolinium dose) will be obtained to measure pulmonary vein flow. CMR sequences to characterize left atrial function, including phasic volumes and emptying fractions (total, passive, active) will also be performed. Data on heart rate variability will additionally be collected at pre- and post-PVI clinic visits, as well as the morning after PVI (hospital day 1).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: March 16, 2021
• Est. primary completion date: June 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Paroxysmal or Persistent AF
• Endurance or highly trained athletes (>3H training/week for >10 yrs)
• NSR at time of stress testing

Exclusion Criteria:

• Structural Heart Disease; LVEF <45%
• Moderate or Severe Valvular disease
• eGFR < 30
• Contraindication to MRI
• Less than average functional capacity
• Previous episode of AF of >14 days duration
• Previous pulmonary vein isolation
• Imaging evidence of pulmonary vein stenosis

Related Conditions & MeSH terms

• Athletes
• Atrial Fibrillation
• Catheter Ablation

Intervention

Procedure:
• Pulmonary Vein Isolation
Standard antral pulmonary vein isolation using radiofrequency ablation catheters

Locations

Country	Name	City	State
United States	Cleveland Clinic Foundation	Cleveland	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
The Cleveland Clinic

Country where clinical trial is conducted

United States, 

References & Publications (1)

Calvo N, Mont L, Tamborero D, Berruezo A, Viola G, Guasch E, Nadal M, Andreu D, Vidal B, Sitges M, Brugada J. Efficacy of circumferential pulmonary vein ablation of atrial fibrillation in endurance athletes. Europace. 2010 Jan;12(1):30-6. doi: 10.1093/europace/eup320. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peak Oxygen Consumption (VO2)	Assessed by cardiopulmonary stress testing	up to 6 months
Secondary	Pulmonary vein function	Change in pulmonary vein cross sectional area measured by resting cardiac MRI	1-4 weeks prior to PVI. Reassessed at 6 months post-PVI.
Secondary	Heart Rate Variability	Time and frequency domain analysis of subjects heart rate variability using 5- minute protocol	1-4 weeks prior to PVI. Reassessed at 1 day and 6 months post-PVI.
Secondary	Subjective Assessment of Athletic Performance	Measured by athlete-specific questionnaire	1-4 weeks prior to PVI. Reassessed at 6 months post-PVI.